Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease
Information source: University of Erlangen-Nürnberg
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Primary Hypertension
Intervention: spironolactone (Drug); placebo (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: University of Erlangen-Nürnberg Official(s) and/or principal investigator(s):
Roland E Schmieder, MD, FACP, Principal Investigator, Affiliation: Universität Erlangen-Nurnberg
Overall contact:
Roland E Schmieder, MD, Phone: 0049 9131, Ext: 8536245, Email: roland.schmieder@uk-erlangen.de
Summary
The Renin-Angiotensin-Aldosterone-system is important in the development of cardiovascular
organ damage caused by arterial hypertension. This study aims at evaluating the importance
of aldosterone with regard to hypertension induced damage to the heart. In order to do this
the investigators will perform a comparative cross-sectional study in hypertensives and
normotensives. In addition as interventional part the hypertensives will be treated with a
mineralocorticoid-receptor blocker (spironolactone).
Clinical Details
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Crossover Assignment, Efficacy Study
Primary outcome: left ventricular mass
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Clinical diagnosis hypertension (BP higher than 139/89)
Exclusion Criteria:
- Antihypertensive pretreatment
- Contraindications against spironolactone
- Being unable to understand or comply with study procedures
Locations and Contacts
Roland E Schmieder, MD, Phone: 0049 9131, Ext: 8536245, Email: roland.schmieder@uk-erlangen.de
University Erlangen-Nürnberg, Nephrology and Hypertension, Erlangen 91054, Germany; Recruiting
Roland E Schmieder, MD, Phone: 0049 9131 85, Ext: 36245, Email: roland.schmieder@uk-erlangen.de
Additional Information
Starting date: March 2008
Ending date: May 2009
Last updated: September 24, 2009
|
